XML 156 R99.htm IDEA: XBRL DOCUMENT v3.22.4
Share-based compensation, Non-vested Share Awards (Details)
 12 Months Ended 74 Months Ended
Dec. 31, 2022
CHF (SFr)
EquityInstruments
Dec. 31, 2021
CHF (SFr)
EquityInstruments
Dec. 31, 2020
CHF (SFr)
EquityInstruments
Dec. 31, 2022
CHF (SFr)
EquityInstruments
Weighted Average grant date fair value [Abstract]        
Expense charged against the income statement | SFr SFr 3,300,000 SFr 4,100,000 SFr 4,100,000  
Directors [Member]        
Share-based payment arrangement [Abstract]        
Vesting conditions 1 year      
Non-vested Share Awards [Member]        
Share-based payment arrangement [Abstract]        
Number of non-vested share awards granted (in shares) 239,194   0  
Number of non-vested shares [Abstract]        
Non-vested at beginning of period (in shares) 797 19,494 42,763  
Forfeited during the year (in shares)     (11,828)  
Expired during the year (in shares)     (7,804)  
Exercised during the year (in shares)   (2,471) (84,638)  
Granted during the year (in shares) 239,194   0  
Vested during the year (23,505) (18,697) (23,269)  
Non-vested at end of period (in shares) 216,486 797 19,494 216,486
Vested and exercisable (in shares) 89,020 65,515 49,289 89,020
Weighted Average grant date fair value [Abstract]        
Weighted average grant date fair value, non-vested at beginning of period | SFr SFr 9.41 SFr 9.51 SFr 9.52  
Weighted average grant date fair value, forfeited during the year | SFr     9.47  
Weighted average grant date fair value, expired during the year | SFr     9.52  
Weighted average grant date fair value, exercised during the year | SFr   9.46 9.51  
Weighted average grant date fair value, granted during the year | SFr 3.06   0  
Weighted average grant date fair value, vested during the year | SFr 3.28 9.52 9.52  
Weighted average grant date fair value, vested and exercisable | SFr 7.84 9.48 9.47 SFr 7.84
Weighted average grant date fair value, non-vested at end of period | SFr 3.06 9.41 9.51 3.06
Restricted Stock Units        
Weighted Average grant date fair value [Abstract]        
Weighted average grant date fair value, non-vested at beginning of period | SFr 9.41 9.51    
Weighted average grant date fair value, non-vested at end of period | SFr SFr 3.06 SFr 9.41 SFr 9.51 SFr 3.06
Restricted Stock Units | Directors [Member]        
Share-based payment arrangement [Abstract]        
Number of non-vested share awards granted (in shares)       159,025
Contractual life of options 10 years      
Number of non-vested shares [Abstract]        
Granted during the year (in shares)       159,025
Restricted Stock Units | Executives [Member]        
Share-based payment arrangement [Abstract]        
Number of non-vested share awards granted (in shares)       274,872
Contractual life of options 10 years      
Number of non-vested shares [Abstract]        
Granted during the year (in shares)       274,872
Restricted Stock Units, first vesting conditions | Executives [Member]        
Share-based payment arrangement [Abstract]        
Vesting conditions 3 years      
Restricted Stock Units, second vesting conditions | Executives [Member]        
Share-based payment arrangement [Abstract]        
Vesting conditions 4 years